INGELHEIM, Germany--()--Data from the PrimoTinA-asthmaTM Phase III studies presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that tiotropium significantly reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICSB/LABAC.1
“These results exceeded our expectations. While we were anticipating improvements in lung function when adding tiotropium to usual care, the significant reduction in the risk of exacerbations came as a surprise – especially given that all patients were already receiving optimal maintenance treatment as defined by the GINA guidelines.”
Tiotropium also significantly improved lung function in symptomatic asthma patients on ICS/LABA.2
These data are also being published simultaneously online in the New England Journal of Medicine available at http://www.nejm.org.
Professor Huib A M Kerstjens of the University Medical Centre, Groningen, The Netherlands, and lead author on both studies, said: “These results exceeded our expectations. While we were anticipating improvements in lung function when adding tiotropium to usual care, the significant reduction in the risk of exacerbations came as a surprise – especially given that all patients were already receiving optimal maintenance treatment as defined by the GINA guidelines.”
The PrimoTinA-asthmaTM studies were two replicate double-blind parallel-group trials including asthma patients with post-bronchodilator FEV1D <80% predicted and asthma control questionnaire score ≥1.5 while on at least ICS/LABA. A total of 912 patients were randomised to additional tiotropium Respimat® 5 μg or placebo for 48 weeks.
The pre-specified co-primary lung function endpoints included peak and trough FEV1 at 24 weeks. Adding tiotropium Respimat® provided significant lung function improvements at 24 weeks, which were sustained over 48 weeks.2
For the third co-primary endpoint, in the pre-specified combined analysis of the two trials, the addition of tiotropium Respimat® was associated with a 21% risk reduction (HR 0.79, P=0.03) in time to first severe exacerbation. Severe exacerbations were defined as requiring systemic corticosteroids for at least 3 days.1
Furthermore, the addition of tiotropium Respimat® reduced the risk of any asthma exacerbation, defined by a significant increase in symptoms or peak expiratory flow (PEF) drop ≥30% over ≥2 days, by 31% (P<0.0001).1
There were also significant improvements in asthma control and asthma related quality of life (evaluated by the questionnaires ACQ and AQLQ) in one trial, and a trend towards improvement in asthma control in the other study.1,2
Despite current treatment options, there still remains an unmet medical need in asthma, because a significant proportion of patients remain symptomatic and may experience asthma exacerbations.3
UniTinA-asthmaTM Phase III trial programme ongoing
The PrimoTinA-asthmaTM studies are part of Boehringer Ingelheim’s comprehensive ongoing Phase III trial programme named UniTinA-asthmaTM, which was designed to establish the efficacy and safety of tiotropium, delivered by the Respimat® SoftMistTM Inhaler (SMI) in patients with asthma. UniTinA-asthmaTM includes a number of clinical studies in adults, adolescents and and children (age 1+) with persistent asthma across the spectrum of asthma severity. These studies involve over 4000 patients in more than 150 sites globally.
Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim, said: “We are excited by these results, which will likely be highly appreciated by both physicians and patients. The UniTinA-asthmaTM trial programme is exploring whether tiotropium can address the clear unmet medical need seen in the significant number of asthma patients who remain symptomatic despite the available therapeutic options. This programme demonstrates our commitment to develop tiotropium Respimat® for a wide range of asthma patients. These first results give us confidence that tiotropium Respimat® has the potential to become an important new option in asthma treatment.”
European Respiratory Society Annual Congress 2012 Boehringer Ingelheim tiotropium in asthma data
Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
|Session:||C8, Session 214, 08:30-10:30, Monday, 03 September 2012|
Tiotropium provides sustained bronchodilation in asthmatics with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
|Session:||Halle A-11, Session 249, 12:50-14:40, Monday, 03 September 2012|
A Tiotropium delivered by Respimat® is not licensed for the treatment of asthma
B Inhaled corticosteroids
C Long-acting beta2-agonists
D FEV1 Forced Expiratory Volume in one second
– Ends –
Please click on the link below for ‘Notes to Editors’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/03_september_2012asthma.html
1. Kerstjens HAM, Engel M, Dahl R, et al. Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. N Eng J Med Published online 3 Sept 2012 (www.nejm.org).
2. Kerstjens HAM, Paggiaro PL, Vandewalker et al. Tiotropium provides sustained bronchodilation in asthmatics with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines. ERS 2012 abstract P2187.
3. Rabe, KF, Vermeire, PA, Soriano, JB, et al Clinical management of asthma in 1999: the Asthma Insights in Europe (AIRE) study. Eur Respir J 2000; 16, 802-807.
4. Global Initiative for Asthma (GINA). http://www.ginasthma.org/Questions-and-answers/q-a-general-information-about-asthma.html [Last Accessed 19/06/12].
5. World Health Organization. WHO factsheet 206: bronchial asthma. Available at: www.who.int/mediacentre/factsheets/fs206/en [Last Accessed 19/06/12].
6. European Federation of Allergy and Airway Diseases Patients Association. http://www.efanet.org/asthma/index.html [Last Accessed 19/06/12].
7. http://www.ginasthma.org/pdf/GINABurdenReport.pdf published in 2003 [Last Accessed 19/06/12].
8. Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004; 114(1): 40-7.
9. Dhand R. Aerosol Plumes: Slow and Steady Wins The Race. J Aerosol Med 2005; 18(3): 261-63.
10. Hochrainer D, Hölz H. Comparison of Aerosol Velocity and Spray Duration of Respimat® Soft MistTM Inhaler and Pressurized Metered Dose Inhalers. J Aerosol Med 2005; 18(3): 273-282.
11. Freytag F, Golisch W, Wolf K. New soft mist inhaler is effective and easy to use in patients with asthma and COPD. Eur Respir J 2005;26(Suppl 49):338s.
12. Brand P et al. Respimat® Soft MistTM inhaler preferred to Diskus® by Patients with COPD and /or Asthma. J Aerosol Med 2007; 20(2): 165.
13. Hodder R, Price D. Patient Preference for Inhaler Devices in Chronic Obstructive Pulmonary Disease: Experience with Respimat® Soft MistTM Inhaler. Int J Chronic Obstruct Pulm Dis 2009; 4: 381-390.
14. Hodder R, Reese PR, Slaton T. Asthma Patients Prefer Respimat® Soft MistTM Inhaler to Turbohaler. Int J Chronic Obstruct Pulm Dis 2009; 4: 225-232.
15. Schuermann W, Schmidtmann S, Moroni P, et al. Respimat® Soft MistTM Inhaler versus hydrofluroalkane metered dose inhaler: patient preference and satisfaction. Treatm Respir Med 2005; 4: 53-61.